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Background: There is very limited information on the relationship between non-alcoholic
fatty liver disease (NAFLD) and the severity or functional outcomes of ischemic stroke
or transient ischemic stroke (TIA). We investigated the correlation between NAFLD and
stroke outcomes.
Methods: NAFLD was assessed in 321 patients with first-ever acute ischemic stroke or
TIA, who underwent transient elastography from January 2014 to December 2014. The
association of liver steatosis with stroke severity, assessed using the National Institute
of Health Stroke Scale (NIHSS), was investigated using robust regression analysis. We
also compared the functional outcome at 90 days according to the presence or burden
of liver steatosis.
Results: NAFLD was observed in 206 (64.2%) patients. Patients with NAFLD had less
severe stroke (median NIHSS score 2 vs. 3, P = 0.012) and more favorable functional
outcome at 90 days (85.3 vs. 70.5, P = 0.004). Patients with NAFLD were likely to have
a 23.3% lower [95% confidence interval (CI), −39.2 to −3.2%, P = 0.026] NIHSS score
and a 2.5-fold higher (95% CI, 1.08–5.67, P = 0.033) possibility of favorable functional
outcome in multivariate analysis.
Conclusions: Our study shows that a higher burden of liver steatosis seems to be
associated with less severe stroke and better functional outcome after ischemic stroke
or TIA.
Keywords: stroke, transient ischemic attack, non-alcoholic fatty liver disease, stroke severity, stroke
functional outcome
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases from simple steatosis to
steatohepatitis with varying degree of fibrosis, and liver cirrhosis (1, 2). NAFLD is becoming the
most common chronic liver disease worldwide including Korea, affecting approximately 25% of
the general population (3, 4). NAFLD is closely associated with obesity, insulin resistance, and type
2 diabetes mellitus, and is even recognized as a manifestation of metabolic syndrome in the liver
(5). Furthermore, NAFLD is known to be clearly associated with cardiovascular morbidity and
mortality (6, 7), and liver fibrosis is especially considered the key determinant (7–11).
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Ischemic stroke is also suggested to be associated with
NAFLD, especially liver fibrosis (7, 10, 12). In the previous study,
we found that there was 41.5% of patients with NAFLD in
ischemic stroke patients (10), similar with previous reports (23.0–
42.7%) from other countries (12–14). However, there is a paucity
of studies attempting to find the association between NAFLD and
the stroke severity or functional outcome after ischemic stroke
(12, 14, 15). Some previous studies, which defined NAFLD as
the presence of elevated aminotransferase levels without apparent
causes (12, 14, 15), failed to show a statistically significant
association between NAFLD and stroke outcomes (12, 15).
Therefore, we sought to assess the association between
NAFLD and the severity or functional outcome in patents
with ischemic stroke. In this study, the presence of NAFLD
was based on transient elastography (TE), which is known
to be a well-qualified method for the diagnosis of NAFLD
and could separately evaluate the degree of liver steatosis and
stiffness (16, 17).
MATERIALS AND METHODS
Patients and Evaluation
This was a retrospective, hospital-based observational study of
patients with acute ischemic stroke or transient ischemic stroke
(TIA) who were prospectively registered in the Yonsei Stroke
Registry. The registry enrolls patients with acute ischemic stroke
or TIA within 7 days of stoke onset who are admitted to the
Severance Stroke Center, Seoul, Korea (18). All patients were
thoroughly evaluated and managed according to the stroke care
protocol based on current stroke guidelines.
Patients who were admitted from January 2014 to December
2014 and underwent TE as a protocol, were evaluated to
investigate the association between NAFLD and ischemic stroke.
Of the 479 included patients, patients with invalid or failed TE
results, chronic viral or autoimmune hepatitis, heavy alcohol
ingestion, and insufficient laboratory or clinical data were
excluded. Additionally, we excluded 74 patients with a previous
ischemic stroke. Finally, 321 patients were enrolled for this
study (Figure 1).
This study was approved by the institutional review board of
Severance Hospital, Yonsei University Health System. Informed
consent was waived owing to the retrospective nature of
the study.
Liver Disease Evaluation
During the study period, all patients underwent TE examination.
We used TE to evaluate liver parameters, instead of standard
ultrasonography, because it is objective and reproducible
method with a low inter-observer variability (19). Also,
it expresses the degree of liver steatosis in a continuous
manner as controlled attenuation parameter (CAP) and offer
simultaneous measurements of liver stiffness (16, 17). The
detailed methodology has been described in our previous studies
(10, 20). The TE results for the degree of liver fibrosis were
expressed as kilopascals (kPa) for liver stiffness (LS), and the
degree of liver steatosis was expressed as CAP values. On the basis
of previous studies, advanced liver fibrosis was defined as an LS
FIGURE 1 | Patient selection.
value of >8.0 kPa (21, 22). For the presence of NAFLD based
on CAP values, NAFLD was defined as a CAP value of >222
dB/m (23).
Clinical Variables and Severity or Favorable
Functional Outcome of Stroke
We collected the patients’ data on vascular risk factors such as
hypertension, diabetes, dyslipidemia, and body mass index (BMI,
kg/m2); metabolic syndrome according to National Cholesterol
Education Program Expert Panel and Adult Treatment Panel
III criteria; current smoking; atrial fibrillation; and history of
ischemic heart disease, ischemic stroke, or peripheral artery
occlusive disease. We collected laboratory data including platelet
count (×103/µL), aspartate aminotransferase (µkat/L), alanine
aminotransferase (µkat/L), estimated glomerular filtration rate
(mL·min−1·1.73 m−2), total cholesterol (mmol/L), triglycerides
(mmol/L), high-density cholesterol (mmol/L), low-density
cholesterol (mmol/L), and fasting blood glucose (mmol/L). Data
on the duration (days) of hospitalization at the department
of neurology were also collected. The subtype of stroke was
determined based on Trial of ORG 10172 in Acute Stroke
Treatment (TOAST) classification (24).
Stroke severity was assessed using the National Institute
of Health Stroke Scale (NIHSS) by the stroke neurologists at
admission. After discharge or transfer to other departments or
institutionalized facilities, regular follow-up was implemented
through routine outpatient clinic visits or telephone interviews. A
favorable functional outcome at 90 days was defined as amodified
Rankin scale score of 0–2 at 90 days after ischemic stroke or TIA.
Statistical Analyses
Statistical and graphical analyses were performed using R version
3.4.2 (http://www.R-project.org). Univariate analysis was carried
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TABLE 1 | Demographic characteristics of study patients according to the presence of NAFLD.
Total
(n = 321)
NAFLD (–)
(n = 115)
NAFLD (+)
(n = 206)
P-value
DEMOGRAPHIC VARIABLES
Age, years 67.0 [56.0 to 74.0] 70.0 [58.5 to 76.0] 66.0 [56.0 to 73.0] 0.011
Sex, men 191 (59.5) 66 (57.4) 125 (60.7) 0.648
Hypertension 232 (72.3) 74 (64.3) 158 (76.7) 0.025
Diabetes 105 (32.7) 33 (28.7) 72 (35.0) 0.307
Dyslipidemia 56 (17.4) 13 (11.3) 43 (20.9) 0.044
Metabolic syndrome 166 (51.7) 44 (38.3) 122 (59.2) <0.001
Body mass index, kg/m2 23.6 [21.8 to 25.8] 21.8 [20.0 to 23.3] 24.6 [22.9 to 26.8] <0.001
Smoker 77 (24.0) 36 (31.3) 41 (19.9) 0.031
Ischemic heart disease 118 (36.8) 40 (34.8) 78 (37.9) 0.668
Peripheral artery occlusive disease 56 (17.4) 21 (18.3) 35 (17.0) 0.893
Atrial fibrillation 27 (8.4) 14 (12.2) 13 (6.3) 0.108
STROKE VARIABLES
NIHSS at admission 2.0 [1.0 to 5.0] 3.0 [1.0 to 6.0] 2.0 [0.0 to 4.0] 0.012
TOAST classification (n = 290) 0.364
Cardioembolism 107 (36.9) 43 (40.2) 64 (35.0)
Large artery atherosclerosis 39 (13.4) 11 (10.3) 28 (15.3)
Lacunar 13 (4.5) 5 (4.7) 8 (4.4)
Other determined etiology 18 (6.2) 3 (2.8) 15 (8.2)
Negative evaluation 37 (12.8) 14 (13.1) 23 (12.6)
More than two causes 76 (26.2) 31 (29.0) 45 (24.6)
Duration of hospitalization 6.0 [5.0 to 9.0] 7.0 [5.0 to 10.0] 6.0 [4.0 to 8.0] 0.020
Favorable mRS at 90 days (n = 289) 231 (79.9) 74 (70.5) 157 (85.3) 0.004
LABORATORY VARIABLES
Aspartate aminotransferase, µkat/L 0.4 [0.3 to 0.5] 0.4 [0.3 to 0.5] 0.4 [0.3 to 0.5] 0.441
Alanine aminotransferase, µkat/L 0.3 [0.2 to 0.4] 0.3 [0.2 to 0.3] 0.3 [0.2 to 0.5] <0.001
Platelet count, ×103/mm3 229.0 [192.0 to 275.0] 222.0 [181.0 to 276.0] 237.0 [197.0 to 275.0] 0.221
Fasting blood glucose, mmol/L 5.8 [5.2 to 7.1] 5.6 [5.0 to 7.2] 5.9 [−5.2 to 7.0] 0.193
eGFR, mL·min−1·1.73 m−2 89.0 [76.0 to 90.0] 90.0 [80.0 to 90.0] 88.5 [75.0 to 90.0] 0.215
Total cholesterol, mmol/L 4.3 [3.7 to 5.0] 4.2 [3.6 to 4.9] 4.4 [3.7 to 5.1] 0.260
Triglyceride, mmol/L 1.2 [0.8 to 1.6] 1.0 [0.7 to 1.4] 1.3 [−0.9 to 1.7] <0.001
High-density lipoprotein, mmol/L 1.1 [0.9 to 1.3] 1.1 [1.0 to 1.3] 1.0 [0.9 to 1.2] 0.009
Low-density lipoprotein, mmol/L 2.6 [2.0 to 3.3] 2.5 [2.0 to 3.0] 2.6 [2.0 to 3.4] 0.288
LIVER VARIABLES
Liver stiffness, kPa 4.7 [4.0 to 6.1] 4.6 [4.0 to 5.8] 4.7 [4.0 to 6.3] 0.750
Advanced fibrosis, >8 kPa 32 (10.0) 11 (9.6) 21 (10.2) >0.999
CAP, dB/m 241.0 [207.0 to 275.0] 197.0 [177.0 to 209.5] 261.0 [242.0 to 289.0] <0.001
NAFLD, non-alcoholic fatty liver disease; NIHSS, National Institute of Health Stroke Scale; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; mRS, modified Rankin scale; eGFR,
estimated glomerular filtration rate; CAP, controlled attenuation parameter. Data are given as median [interquartile range] or number (%).
out with the independent t-test, or Mann-Whitney U-test for
continuous variables and the χ2-test for categorical variables as
appropriate. NIHSS was modeled as the natural logarithm of
NIHSS plus 1 for skewness. Because of the lack of normality
of the residuals for the NIHSS model, we used ordinary
linear regression with robust standard errors to investigate the
association between NIHSS score and liver steatosis, because
residuals of the NIHSS model showed lack of normality.
Determinants for favorable functional outcome were investigated
using logistic regression analysis. Multivariate analysis was
conducted with adjustments for age, sex, hypertension, diabetes
mellitus, hypercholesterolemia, metabolic syndrome, BMI, and
variables with P < 0.05 in univariate analysis. Finally, P < 0.05
was considered statistically significant.
RESULTS
Baseline Characteristics
The baseline characteristics of the patients are presented in
Table 1. Among 321 patients enrolled in this study, 206 (64.2%)
patients had NAFLD based on the predetermined definition.
Patients with NAFLD were more likely to be younger and
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FIGURE 2 | Stroke severity according to the presence of NAFLD (A) or advanced fibrosis (B). NIHSS, National Institute of Health Stroke Scale; NAFLD, non-alcoholic
fatty liver disease.
to have hypertension; dyslipidemia; metabolic syndrome; no
smoking habit; higher BMI, alanine aminotransferase level, or
triglyceride level; and lower high-density lipoprotein level. There
was no difference in the degree of liver fibrosis and distribution
of strokes according to TOAST criteria between patients with
and without NAFLD. Also, distribution of strokes according
to TOAST criteria showed no difference according to whether
patients were included or excluded (p > 0.05, data not shown).
Stroke Severity and NAFLD
The median NIHSS score was 2 (interquartile range [IQR], 1–
5). There were differences in NIHSS scores between patients
with NAFLD and those without (median [IQR], 2 [0–4]
vs. 3 [1–6], P = 0.012; Figure 2A). Patients with NAFLD
had a shorter duration of hospitalization than those without
(median [IQR], 6 [4–8] vs. 7 [5–10], P = 0.02; Table 1).
However, the NIHSS score did not differ according to the
presence of advanced fibrosis (P = 0.711, Figure 2B). In
univariate robust linear regression analysis, the NIHSS score
was associated with the burden of liver steatosis (P =
0.022) or NAFLD (P= 0.012), along with diabetes (P =
0.023), atrial fibrillation (P = 0.036), or peripheral artery
occlusive disease (P = 0.032) (Table 2). In multivariate analysis,
patients with NAFLD showed a 23.3% lower [95% confidence
interval (CI) −39.2 to −3.2%, P = 0.026] NIHSS score than
patients without NAFLD (Table 3). When parameters were
used as continuous variables, such association was consistently
noted (P = 0.039, Table 3). Advanced fibrosis or the burden
of LS was not significantly associated with stroke severity
(P > 0.05, Table 3).
Favorable Functional Outcome at 90 Days
and NAFLD
The functional outcome at 90 days could be assessed among
289 patients. Patients with NAFLD were more likely to
have a favorable functional outcome at 90 days than those
without (157 [85.3%] vs. 74 [70.5%], P = 0.004; Figure 3).
In univariate logistic regression analysis, age, male sex,
hypertension, NIHSS score, duration of hospitalization,
steatosis, or NAFLD was associated with a favorable
functional outcome at 90 days (Table 2). In multivariate
analysis, patients with NAFLD showed a 2.5-fold higher (OR
2.45, 95% CI 1.08–5.67, P = 0.033) possibility of favorable
functional outcome (Table 3). This association was consistent
when parameters were used as continuous variables (P =
0.026, Table 3). Advanced fibrosis or the burden of LS
showed no significant association with functional outcome
(P > 0.05, Table 3).
DISCUSSION
In this study, we found that NAFLD, not advanced fibrosis,
was an independent predictor of less severe stroke and more
favorable functional outcome at 90 days in patients with
first-ever ischemic stroke or TIA. Those associations were
consistent even after adjustment for a variety of known vascular
risk factors, and even when liver parameters were used as
continuous variables.
NAFLD is not a single disease entity but a spectrum of
diseases, including simple fatty liver, steatohepatitis with fibrosis,
and liver cirrhosis (1, 2). Previous studies evaluating the
significance of liver fibrosis or steatosis suggested that liver
fibrosis, rather than NAFLD, might act as a key prognostic factor
for long-term clinical outcome (7–9, 11). Hepatic stellate cells,
which play a critical role in liver inflammation and fibrogenesis,
have been known to involve the elevation of circulating levels
of several inflammatory, procoagulant, and oxidative stress
markers, and to cause poor vascular outcomes (25). In our
previous studies, we also indicated that advanced liver fibrosis
might be a predictor of the occurrence of ischemic stroke and
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TABLE 2 | Univariate regression analysis.
NIHSS
(n = 321)
Favorable functional outcome
(n = 289)
Estimate (95% CI) P-value Estimate (95% CI) P-value
DEMOGRAPHIC VARIABLES
Age, years 0.3% (−0.5 to 1.1%) 0.416 0.93 (0.91 to 0.96) <0.001
Sex, men 11.1% (−18.6 to 22.8%) 0.996 1.90 (1.06 to 3.41) 0.030
Hypertension −7.2% (−26 to 16.3%) 0.516 0.33 (0.14 to 0.70) 0.007
Diabetes 28.4% (3.6 to 59.1%) 0.023 0.62 (0.34 to 1.12) 0.109
Dyslipidemia 6.9% (−18 to 39.5%) 0.621 1.39 (0.64 to 3.36) 0.431
Metabolic syndrome 4.2% (−14.8 to 27.3%) 0.689 0.68 (0.37 to 1.21) 0.188
Body mass index, kg/m2 −2% (−4.8 to 0.9%) 0.174 1.06 (0.98 to 1.16) 0.162
Smoker 21.9% (−3.5 to 53.8%) 0.097 1.80 (0.89 to 3.96) 0.120
Atrial fibrillation 32.6% (2 to 72.3%) 0.036 0.51 (0.26 to 1.04) 0.057
Ischemic heart disease −69.2% (−75 to −62.1%) 0.093 1.50 (0.82 to 2.82) 0.198
Peripheral artery occlusive disease 45.5% (1.5 to 108.6%) 0.042 0.47 (0.19 to 1.29) 0.122
STROKE VARIABLES
NIHSS at admission 0.83 (0.77 to 0.88) <0.001
Duration of hospitalization (days) 0.79 (0.73 to 0.86) <0.001
LABORATORY VARIABLES
Aspartate aminotransferase, µkat/L −24.7% (−51.7 to 17.3%) 0.210 0.60 (0.19 to 2.15) 0.399
Alanine aminotransferase, µkat/L −25.6% (−44.5 to −0.3%) 0.048 2.49 (0.86 to 11.18) 0.163
Platelet count, ×103/mm3 0% (−0.1 to 0.1%) 0.819 1.00 (1.00 to 1.00) 0.725
Fasting blood glucose, mmol/L 4.7% (1.3 to 8.3%) 0.007 0.95 (0.86 to 1.04) 0.212
eGFR, 0.2% (−0.4 to 0.8%) 0.538 1.01 (0.99 to 1.02) 0.432
Total cholesterol, mmol/L 7.7% (−1.5 to 17.8%) 0.102 0.97 (0.75 to 1.26) 0.804
Triglyceride, mmol/L −0.2% (−9.8 to 10.4%) 0.968 1.40 (0.96 to 2.24) 0.127
High-density lipoprotein, mmol/L −6.1% (−33.6 to 32.7%) 0.721 1.02 (0.39 to 2.85) 0.967
Low-density lipoprotein, mmol/L 12.3% (1.2 to 24.7%) 0.030 0.89 (0.66 to 1.21) 0.443
LIVER VARIABLES
Liver stiffness, kPa 1.6% (−1 to 4.2%) 0.236 0.96 (0.89 to 1.02) 0.159
Advanced fibrosis, >8 kPa 5.6% (−24.5 to 47.8%) 0.750 0.77 (0.32 to 2.03) 0.565
CAP, dB/m −0.3% (−0.5 to 0%) 0.022 1.01 (1.01 to 1.02) <0.001
NAFLD, >220dB/m −24.9% (−39.8 to −6.3%) 0.012 2.44 (1.36 to 4.40) 0.003
NIHSS, National Institute of Health Stroke Scale; eGFR, estimated glomerular filtration rate; CAP, controlled attenuation parameter; NAFLD, non-alcoholic fatty liver disease. Data are
given as hazard ratio (95% confidence interval).
long-term outcomes of ischemic stroke patients, whereas isolated
liver steatosis was not (10, 11). However, this study implied
that stroke severity was dependent on liver steatosis, not on
liver fibrosis, in patients without a previous ischemic stroke
or TIA.
Considering the potential detrimental effect of NAFLD on
the cardiovascular or cerebrovascular system (6, 7), the presence
of NAFLD could be expected to lead to worse stroke profiles.
However, in terms of the impact of NAFLD on stroke severity
or functional outcome after stroke, there are only a few reports,
which showed contradictory results (12, 14, 15). NAFLD could
be associated with severe stroke or neurological deterioration
during hospitalization in a specific stroke population such as
patients with brainstem infarction (14). Some other studies
conducted in the overall stroke population showed that the
presence of NAFLD had some detrimental or neutral effects
on the stroke severity. However, in those studies, the stroke
severity was compared without adjusting for any potential
confounders (12), or with only a small number of patients
with NAFLD (15). Furthermore, NAFLD was defined based
on a relatively arbitrary definition, such as aminotransferase
level above the upper limit, which also led to some different
results (2, 12, 15, 17). In our analysis based on TE including
the overall stroke population, the presence or burden of
NAFLD was found to be associated with mild stroke or
favorable functional outcome even after adjustment for potential
confounding factors.
The exact mechanism of this paradoxical phenomenon is
not clear. However, our results could be disputed because
of the differences in baseline demographics. In our analysis,
although patients with NAFLD were more likely to have
co-morbidities such as hypertension, dyslipidemia, metabolic
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TABLE 3 | Multivariate regression analysis of the degree of liver fibrosis and steatosis.
NIHSS (n = 321) Favorable functional outcome (n = 289)
Estimate (95% CI) P-value Estimate (95% CI) P-value
PARAMETERS AS CONTINUOUS VARIABLES
Liver steatosis, per 1 dB/m −0.3% (−0.5 to 0%) 0.039 1.01 (1 to 1.02) 0.026
Liver stiffness, kPa 1.4% (−1.4 to 4.3%) 0.319 0.96 (0.88 to 1.05) 0.341
PARAMETERS AS CATEGORIAL VARIABLES
NAFLD, >220 dB/m −23.3% (−39.2 to −3.2%) 0.026 2.45 (1.08 to 5.67) 0.033
Advanced fibrosis, >8 kPa −2.9% (−31 to 36.8%) 0.868 0.71 (0.23 to 2.38) 0.559
NIHSS, National Institute of Health Stroke Scale; NAFLD, non-alcoholic fatty liver disease. Adjusted for age, sex, hypertension, diabetes, dyslipidemia, metabolic syndrome, body mass
index, and variables with p < 0.05 in univariate analysis. Data are given as hazard ratio (95% confidence interval).
FIGURE 3 | Distribution of functional outcome at 90 days according to the presence of NAFLD. A total of 32 patients without modified Rankin scale (mRS) scores in
90-day data were excluded. NAFLD, non-alcoholic fatty liver disease; mRS, modified Rankin scale.
syndrome, or higher BMI etc., the proportion of significant
factors affecting the NIHSS score, such as diabetes, atrial
fibrillation, or peripheral arterial occlusive disease, was similar
between the 2 groups, or even lower in patients with NAFLD
than in those without NAFLD. Furthermore, in our study,
patients with NAFLD were actually 4 years younger than
patients without NAFLD and had higher BMI. Previously, the
obesity paradox for BMI and the risk of stroke or stroke
outcome was proposed (26). These imbalances of underlying
co-morbidities could have caused inverse relationship between
liver steatosis and systemic inflammatory damages and finally
led to paradoxical protective effect of liver steatosis on severity
and functional outcome of ischemic stroke. However, the
association between NAFLD and favorable outcome persisted
even after extensive covariate adjustment for all favorable
baseline characteristics.
One limitation of our study is that the retrospective
single-center design might have caused a selection bias.
However, no patient selection for performing TE was conducted
in our study cohort. Another possible limitation is that
liver status was not evaluated using liver biopsy, which
is a gold standard method for the evaluation of NAFLD
(1, 2). Nevertheless, TE is a well-established method (16,
17), and there is limitation in conducting liver biopsy in
patients with acute stroke within acute stroke period. One
more limitation is that we did not evaluated inflammatory,
procoagulant, and oxidative stress markers, which are well-
known to connect liver pathology with vascular outcomes (25).
By measuring these markers and investigate the association of
liver parameters and stroke outcomes with them, we could
reveal that the paradoxical protective effect of liver steatosis
is just a bystander phenomenon or one of under-recognized
cascades. Future prospective study with those markers might
be warranted.
In conclusion, a higher burden of liver steatosis, NAFLD,
seems to be associated with less severe stroke and better
functional outcome after ischemic stroke or TIA. This
paradoxical association may be causally related or a kind of
an epiphenomenon. Further studies are needed to clarify the
possible mechanism.
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